Objectives: The effectiveness of tocilizumab (TOC) for JIA related uveitis (JIA-U) were reported in refractory cases against TNF inhibitors and TOC is proposed as one of third-line therapy in 2019 JIA uveitis guideline of ACR (recommendation 15). The gene discussed is TNF; the disease is uveitis.